Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).

Ghassan K Abou-Alfa,George Lau,Masatoshi Kudo,Stephen L Chan,Robin Kate Kelley,Junji Furuse,Wattana Sukeepaisarnjaroen,Yoon Koo Kang,Tu Van Dao,Enrico N De Toni,Lorenza Rimassa,Valeriy Breder,Alexander Vasilyev,Alexandra Heurgué,Vincent C Tam,Kabir Mody,Satheesh Chiradoni Thungappa,Yurii Ostapenko,Thomas Yau,Sergio Azevedo,María Varela,Ann-Lii Cheng,Shukui Qin,Peter R Galle,Sajid Ali,Charu Gupta,Mallory Makowsky,John F Kurland,Alejandra Negro,Bruno Sangro

Future oncology (London, England)（2023）

Cited 0|Views41
No score
Abstract
Overall, STRIDE is more effective than sorafenib for people with unresectable HCC. NCT03298451 (HIMALAYA) (ClinicalTrials.gov).
More
Translated text
Key words
clinical trial, durvalumab, hepatocellular carcinoma, immunotherapy, lay summary, liver cancer, plain language summary, Sorafenib, tremelimumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined